Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SRS001
MIFTS: 51

Serous Cystadenocarcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Serous Cystadenocarcinoma

About this section

MalaCards integrated aliases for Serous Cystadenocarcinoma:

Name: Serous Cystadenocarcinoma 11 14 75
Cystadenocarcinoma, Serous 43 71
Serous Adenocarcinoma 11 16
Cystadenocarcinoma Serous 53
Serous Carcinoma 11

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:3114
MeSH 43 D018284
NCIt 49 C3778
SNOMED-CT 68 90725004
UMLS 71 C0206701
Sources

Summaries for Serous Cystadenocarcinoma

About this section

Disease Ontology: 11 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards based summary: Serous Cystadenocarcinoma, also known as cystadenocarcinoma, serous, is related to peritoneal serous adenocarcinoma and endometrial serous adenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Prolactin Signaling. The drugs Etoposide and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Wikipedia: 75 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...
Sources

Related Diseases for Serous Cystadenocarcinoma

About this section

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 626)
# Related Disease Score Top Affiliating Genes
1 peritoneal serous adenocarcinoma 32.9 WT1 PAX8
2 endometrial serous adenocarcinoma 32.5 WT1 TP53 PTEN POLE PIK3CA KRAS
3 ovarian serous cystadenocarcinoma 32.4 TP53 PTEN PIK3CA PAX8 NF1 MUC16
4 papillary serous adenocarcinoma 32.3 WT1 TP53 PAX8 MIR30A KRAS HRAS
5 appendix adenocarcinoma 32.2 TP53 KRAS HRAS
6 cystadenoma 31.4 PTEN MUC16 BRCA1
7 adenocarcinoma 31.3 TYMP TP53 PTEN PIK3CA MMP2 KRAS
8 cystadenocarcinoma 31.3 WT1 TP53 PTEN PAX8 NF1 MUC16
9 cervical adenocarcinoma 31.1 TP53 MUC16 KRAS
10 endometrial adenocarcinoma 31.1 TP53 PTEN POLE PAX8 MIR199A1 KRAS
11 ovarian cystadenocarcinoma 31.0 TP53 PTEN PIK3CA PAX8 MUC16 MIR30A
12 peritoneal mesothelioma 30.9 WT1 TP53 PAX8
13 endodermal sinus tumor 30.8 MUC16 MIR199A1 ALPP
14 large cell neuroendocrine carcinoma 30.8 TP53 KRAS HRAS
15 fallopian tube carcinoma 30.7 WT1 TP53 PTEN PAX8 BRCA2 BRCA1
16 clear cell adenocarcinoma 30.7 TP53 PAX8 MUC16 ARID1A
17 fallopian tube adenocarcinoma 30.6 WT1 PAX8 BRCA1
18 adenomyosis 30.6 TP53 PTEN MUC16 MMP2 KRAS
19 papillary adenocarcinoma 30.6 TP53 PAX8 MUC16 MIR30A MIR21 KRAS
20 ovarian cystadenoma 30.6 TP53 MUC16 BRCA1
21 ovary transitional cell carcinoma 30.6 BRCA2 BRCA1
22 papillary cystadenocarcinoma 30.6 WT1 TP53 MUC16
23 breast ductal carcinoma 30.6 TP53 PTEN BRCA2 BRCA1
24 endometrial hyperplasia 30.5 TP53 PTEN KRAS ARID1A
25 adenofibroma 30.5 WT1 TP53 PAX8 MUC16 KRAS ARID1A
26 transitional cell carcinoma 30.5 TP53 PTEN MUC16 MMP14
27 rectal benign neoplasm 30.5 TP53 PIK3CA KRAS HRAS
28 leiomyosarcoma 30.5 WT1 TP53 NF1 MUC16 BRCA1
29 adenoma 30.4 TP53 PIK3CA KRAS HRAS
30 ovarian clear cell carcinoma 30.4 WT1 TP53 PTEN PIK3CA MIR21 MIR199A1
31 endometriosis 30.4 TP53 PTEN MUC16 MMP2 MIR199A1
32 endometriosis of ovary 30.4 PTEN PIK3CA MIR199A1 ARID1A
33 carcinosarcoma 30.4 WT1 TP53 PTEN PIK3CA PAX8 KRAS
34 ovarian cancer 30.4 WT1 TYMP TP53 PTEN PIK3CA MUC16
35 tetraploidy 30.4 TP53 BRCA2
36 endometrial squamous cell carcinoma 30.4 TP53 PAX8
37 ovarian clear cell adenocarcinoma 30.3 TP53 PIK3CA ARID1A
38 rectum cancer 30.3 TYMP TP53 MIR30A MIR21 KRAS HRAS
39 ovarian large-cell neuroendocrine carcinoma 30.3 WT1 TP53 PAX8
40 hereditary breast cancer 30.3 BRCA2 BRCA1
41 endometrioid ovary carcinoma 30.3 WT1 TP53 PTEN POLE PIK3CA KRAS
42 bilateral breast cancer 30.3 TP53 PTEN BRCA2 BRCA1
43 endocervical adenocarcinoma 30.3 TP53 PTEN PIK3CA PAX8 HRAS ARID1A
44 vaginal cancer 30.3 TP53 PTEN HRAS BRCA1
45 thyroid cancer, nonmedullary, 2 30.3 PTEN PAX8 HRAS
46 ovarian serous cystadenofibroma 30.3 WT1 TP53 PAX8 BRCA1
47 kidney cancer 30.3 WT1 TP53 PIK3CA MIR30A MIR21 MIR199A1
48 uterine corpus endometrial carcinoma 30.3 TP53 PTEN PIK3CA NF1 KRAS ARID1A
49 mastitis 30.2 PTEN MUC16 MIR21
50 endosalpingiosis 30.2 WT1 TP53 PAX8 KRAS HRAS BRCA2

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to Serous Cystadenocarcinoma
Sources

Symptoms & Phenotypes for Serous Cystadenocarcinoma

About this section

GenomeRNAi Phenotypes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

25 (show top 50) (show all 69)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.59 POLE
2 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.59 WT1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.59 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.59 TP53 KRAS
5 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.59 WT1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.59 POLE
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.59 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.59 BRCA1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.59 BRCA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.59 WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.59 PTEN
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.59 WT1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.59 PTEN
14 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.59 PAX8
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.59 ARID1A BRCA1 POLE PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.59 TP53
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.59 ARID1A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.59 MMP14
19 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.59 TP53
20 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.59 ARID1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.59 TP53
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.59 ARID1A MMP14 TP53
23 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.59 HRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.59 POLE
25 Increased shRNA abundance (Z-score > 2) GR00366-A-20 10.59 TP53
26 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.59 BRCA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.59 POLE
28 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.59 BRCA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.59 ARID1A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.59 WT1 PTEN
31 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.59 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.59 MMP14
33 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.59 HRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.59 WT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.59 POLE
36 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.59 TP53
37 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.59 TP53
38 Increased shRNA abundance (Z-score > 2) GR00366-A-40 10.59 MMP14
39 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.59 PTEN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.59 ARID1A WT1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.59 WT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.59 MMP14
43 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.59 PIK3CA
44 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.59 TP53
45 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.59 KRAS POLE PTEN
46 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.59 PTEN
47 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.59 ARID1A MMP14
48 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.59 HRAS
49 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.59 WT1 POLE
50 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.59 HRAS POLE PTEN

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.38 ARID1A BRCA1 BRCA2 HRAS KRAS MMP14
2 neoplasm MP:0002006 10.37 ARID1A BRCA1 BRCA2 HRAS KRAS MMP2
3 homeostasis/metabolism MP:0005376 10.37 ARID1A BRCA1 BRCA2 HRAS KRAS MMP14
4 normal MP:0002873 10.36 ARID1A BRCA1 BRCA2 HRAS KRAS MMP14
5 endocrine/exocrine gland MP:0005379 10.32 ARID1A BRCA1 BRCA2 HRAS KRAS MMP14
6 muscle MP:0005369 10.29 ARID1A BRCA1 HRAS KRAS MMP14 MMP2
7 renal/urinary system MP:0005367 10.26 BRCA1 HRAS KRAS MMP14 MMP2 NF1
8 embryo MP:0005380 10.24 ARID1A BRCA1 BRCA2 KRAS MMP14 NF1
9 no phenotypic analysis MP:0003012 10.23 ARID1A HRAS KRAS MIR199A1 MMP14 PAX8
10 cellular MP:0005384 10.21 ARID1A BRCA1 BRCA2 KRAS MMP14 NF1
11 digestive/alimentary MP:0005381 10.18 BRCA1 BRCA2 HRAS KRAS MMP14 MMP2
12 cardiovascular system MP:0005385 10.18 ARID1A BRCA1 HRAS KRAS MMP14 MMP2
13 immune system MP:0005387 10.18 ARID1A BRCA1 BRCA2 KRAS MMP14 MMP2
14 limbs/digits/tail MP:0005371 10.14 BRCA1 BRCA2 KRAS MMP14 NF1 PAX8
15 reproductive system MP:0005389 10.07 ARID1A BRCA1 BRCA2 KRAS MMP14 MMP2
16 craniofacial MP:0005382 10.06 ARID1A HRAS KRAS MMP14 MMP2 NF1
17 respiratory system MP:0005388 9.97 BRCA1 HRAS KRAS MMP14 MMP2 NF1
18 skeleton MP:0005390 9.97 ARID1A BRCA1 BRCA2 HRAS KRAS MMP14
19 mortality/aging MP:0010768 9.83 ARID1A BRCA1 BRCA2 HRAS KRAS MIR199A1
20 integument MP:0010771 9.36 BRCA1 BRCA2 HRAS KRAS MMP14 MMP2
Sources

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section

Drugs for Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
2
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
5
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
6
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
7
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
8
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
9
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
10
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
11
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
12
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
13
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
14
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
15
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
16
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
17
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
18
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
19
Tamoxifen Approved Phase 2, Phase 3 10540-29-1, 54965-24-1 2733526
20
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
21
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
23
Oregovomab Investigational Phase 3 213327-37-8
24
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
25
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
26
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-16-7, 110-17-8 444266 444972
27 Carotenoids Phase 3
28
Etoposide phosphate Phase 2, Phase 3 16760419
29 Adjuvants, Immunologic Phase 3
30 Antiviral Agents Phase 3
31 Anti-Infective Agents Phase 3
32 Antimetabolites Phase 3
33 Albumin-Bound Paclitaxel Phase 2, Phase 3
34 Antimitotic Agents Phase 2, Phase 3
35 Tubulin Modulators Phase 2, Phase 3
36 Hypoglycemic Agents Phase 2, Phase 3
37 Estrogen Receptor Antagonists Phase 2, Phase 3
38 Estrogen Antagonists Phase 2, Phase 3
39 Hormones Phase 2, Phase 3
40 Hormone Antagonists Phase 2, Phase 3
41 Aromatase Inhibitors Phase 2, Phase 3
42 Immunoglobulins, Intravenous Phase 2, Phase 3
43 Immunoglobulin G Phase 2, Phase 3
44 Angiogenesis Inhibitors Phase 2, Phase 3
45 Endothelial Growth Factors Phase 2, Phase 3
46 Mitogens Phase 2, Phase 3
47 topoisomerase I inhibitors Phase 2, Phase 3
48 Protein Kinase Inhibitors Phase 2, Phase 3
49 Anti-Bacterial Agents Phase 2, Phase 3
50 Antibiotics, Antitubercular Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 186)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
2 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
3 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Unknown status NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
4 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
5 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
8 Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial) Recruiting NCT05601700 Phase 3 Letrozole tablets;carboplatin AUC 5 and paclitaxel 175 mg/m2
9 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
10 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
11 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
12 A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Recruiting NCT04498117 Phase 3 Paclitaxel;Carboplatin
13 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
14 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan;Trametinib Dimethyl Sulfoxide
15 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
16 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
17 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
18 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
19 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
20 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
21 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
22 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
23 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
24 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
25 A Phase II Trial to Evaluate the Efficacy of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Unknown status NCT03509246 Phase 2 Pegylated liposomal doxorubicin plus Bortezomib
26 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
27 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxaneâ„¢) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
28 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
29 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
30 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
31 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
32 A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum Completed NCT00551070 Phase 2 Selumetinib;Selumetinib Sulfate
33 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
34 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Completed NCT02728258 Phase 2 Copanlisib
35 A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
36 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
37 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
38 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
39 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
40 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
41 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
42 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
43 A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
44 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
45 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
46 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
47 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
48 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
49 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
50 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206

Search NIH Clinical Center for Serous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, serous

Sources

Genetic Tests for Serous Cystadenocarcinoma

About this section
Sources

Anatomical Context for Serous Cystadenocarcinoma

About this section

Organs/tissues related to Serous Cystadenocarcinoma:

MalaCards : Ovary, Lymph Node, Breast, Uterus, Cervix, Endothelial, Liver
Sources

Publications for Serous Cystadenocarcinoma

About this section

Articles related to Serous Cystadenocarcinoma:

(show top 50) (show all 4008)
# Title Authors PMID Year
1
Dipeptidyl peptidase IV in tumor progression. 53 62
16054016 2005
2
Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. 53 62
12019149 2002
3
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential. 53 62
11063654 2000
4
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. 53 62
9852392 1999
5
Solitary splenic metastasis of an adenocarcinoma of the ovaries. 53 62
8938479 1996
6
Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. 53 62
8669868 1995
7
The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125. 53 62
8494699 1993
8
Serum and tissue measurements of CA72-4 in ovarian cancer patients. 53 62
8381375 1993
9
[An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. 53 62
1506732 1992
10
Computed Tomographic Radiomics in Differentiating Histologic Subtypes of Epithelial Ovarian Carcinoma. 62
36469315 2022
11
Endometrial serous carcinoma with extensive squamous differentiation mimicking primary endometrial squamous cell carcinoma: Clinicopathological and molecular analysis of a case with literature review. 62
36423403 2022
12
One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing. 62
36036365 2022
13
Variants of in situ carcinoma of the endometrium: Clear cell and gastrointestinal types, with a review of the literature. 62
36249906 2022
14
Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma. 62
35804040 2022
15
Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice. 62
35916971 2022
16
Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? 62
36423445 2022
17
Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. 62
36428992 2022
18
Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness. 62
36409196 2022
19
Potent Uncompetitive Inhibitors of Nicotinamide N-Methyltransferase (NNMT) as In Vivo Chemical Probes. 62
36288465 2022
20
Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum. 62
35962920 2022
21
The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens. 62
36399408 2022
22
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. 62
36323715 2022
23
Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. 62
36369472 2022
24
Metastatic spread of serous ovarian carcinoma to the bilateral breasts: a rare presentation. 62
36423949 2022
25
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. 62
36323878 2022
26
Serous tubal intra-epithelial carcinoma: what do we really know at this point? 62
35859323 2022
27
Targeted Therapies in the Treatment of Uterine Serous Carcinoma. 62
36447064 2022
28
Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites. 62
36399410 2022
29
Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma. 62
36430324 2022
30
Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions? 62
36459857 2022
31
Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging. 62
36372398 2022
32
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. 62
36063572 2022
33
Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D. 62
36362078 2022
34
Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer. 62
35835930 2022
35
Successful nedaplatin desensitization therapy in a patient with platinum-sensitive recurrent ovarian cancer: A case report and literature review. 62
36118075 2022
36
Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis. 62
36206311 2022
37
Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation. 62
35801373 2022
38
Uterine choriocarcinoma arising from serous carcinoma in a postmenopausal woman: an analysis of next-generation sequencing and PD-L1 immunochemistry. 62
36229840 2022
39
Primary high grade serous carcinoma of the appendix: a diagnostic dilemma. 62
35144828 2022
40
New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma. 62
35234527 2022
41
Clinico-pathological Study of Malignant Ovarian Tumor in a Tertiary Care Hospital. 62
36189550 2022
42
Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance. 62
35920183 2022
43
A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma. 62
35809685 2022
44
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. 62
36243601 2022
45
High expression of the ANXA3 gene promotes immune infiltration and improves tumor prognosis in ovarian serous carcinoma using bioinformatics analyses. 62
36330402 2022
46
Cutaneous metastasis of carcinomatous component of ovarian carcinosarcoma: A case report and review of the literature. 62
36199118 2022
47
IGF-2 mediated hypoglycemia and the paradox of an apparently benign lesion: a case report & review of the literature. 62
36303203 2022
48
Prognostic Significance of Clinical Factors Including BRCA Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer. 62
36191979 2022
49
Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer. 62
36325670 2022
50
Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. 62
36415372 2022
Sources

Variations for Serous Cystadenocarcinoma

About this section
Sources

Expression for Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Serous Cystadenocarcinoma.
Sources

Pathways for Serous Cystadenocarcinoma

About this section

Pathways related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Disease 66
Show member pathways
 13.79 TP53 PTEN PIK3CA NF1 MUC16 KRAS
2
Prolactin Signaling 64
Show member pathways
 13.42 TP53 PTEN PIK3CA NF1 KRAS HRAS
3
PI3K-Akt signaling pathway 74
Show member pathways
 12.9 TP53 PTEN PIK3CA KRAS HRAS BRCA1
4
Endometrial cancer 74
Show member pathways
 12.62 BRCA2 HRAS KRAS NF1 PIK3CA PTEN
5
Malignant pleural mesothelioma 74
12.56 TP53 PTEN PIK3CA MMP2 MMP14 HRAS
6
Immune response IL-23 signaling pathway 22
Show member pathways
 12.53 TP53 PIK3CA MMP2 KRAS HRAS
7
Development EGFR signaling pathway 22
Show member pathways
 12.45 HRAS KRAS PIK3CA TP53
8
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.43 TP53 PTEN PIK3CA HRAS
9
NF-kappaB Pathway 70
Show member pathways
 12.4 HRAS KRAS PIK3CA TP53
10
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.37 PIK3CA MMP2 KRAS HRAS
11
MAPK signaling pathway 74
12.36 TP53 NF1 KRAS HRAS
12
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.31 PIK3CA NF1 KRAS HRAS BRCA1
13
B Cell Receptor Signaling Pathway 67
Show member pathways
 12.28 PTEN PIK3CA KRAS HRAS
14
Development IGF-1 receptor signaling 22
Show member pathways
 12.22 TP53 PTEN PIK3CA HRAS
15
Ras signaling 74
12.2 PIK3CA NF1 KRAS HRAS
16
Colorectal Cancer Metastasis 64
12.14 TP53 MMP2 MMP14 KRAS
17
MAPK Signaling: Mitogens 65
Show member pathways
 12.14 TP53 PTEN PIK3CA KRAS HRAS
18
Breast cancer pathway 74
Show member pathways
 12.13 TP53 PTEN PIK3CA KRAS HRAS BRCA2
19
T-cell activation SARS-CoV-2 74
Show member pathways
 12.1 TP53 PTEN PIK3CA HRAS
20
Epithelial to mesenchymal transition in colorectal cancer 74
12.08 TP53 PIK3CA MMP2 KRAS HRAS
21
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.07 HRAS MMP2 PIK3CA PTEN
22
Integrated breast cancer pathway 74
11.91 TP53 PTEN NF1 KRAS BRCA2 BRCA1
23
Development EGFR signaling via small GTPases 22
Show member pathways
 11.9 HRAS KRAS PIK3CA PTEN
24
Signaling by Erythropoietin 66
Show member pathways
 11.86 PIK3CA KRAS HRAS
25
Senescence and autophagy in cancer 74
11.86 TP53 PTEN MMP14 HRAS
26
DNA damage response (only ATM dependent) 74
11.84 TP53 PTEN PIK3CA KRAS HRAS
27
FGFR1 mutant receptor activation 66
Show member pathways
 11.83 PIK3CA KRAS HRAS
28
Signaling by PDGF 66
Show member pathways
 11.81 PIK3CA KRAS HRAS
29
Thyroid hormones production and peripheral downstream signaling effects 74
11.78 TP53 PIK3CA HRAS
30
BRCA1 Pathway 64
Show member pathways
 11.78 TP53 BRCA2 BRCA1
31
DNA IR-damage and cellular response via ATR 74
11.77 TP53 BRCA2 BRCA1
32
VEGF Pathway (Tocris) 70
Show member pathways
 11.75 PIK3CA KRAS HRAS
33
DAP12 interactions 66
Show member pathways
 11.72 PIK3CA KRAS HRAS
34
mTOR Pathway 70
Show member pathways
 11.71 TP53 PIK3CA KRAS HRAS
35
BCR signaling pathway 61
11.65 PTEN PIK3CA HRAS
36
Serotonin HTR1 group and FOS pathway 74
Show member pathways
 11.62 PIK3CA KRAS HRAS
37
Copper homeostasis 74
Show member pathways
 11.59 TP53 PTEN PIK3CA
38
ATF-2 transcription factor network 61
11.58 NF1 MMP2 BRCA1
39
Head and neck squamous cell carcinoma 74
11.58 HRAS KRAS PIK3CA PTEN TP53
40
BDNF-TrkB signaling 74
Show member pathways
 11.57 PTEN NF1 KRAS HRAS
41
Signaling by PDGFR in disease 66
Show member pathways
 11.52 HRAS KRAS PIK3CA
42
Kisspeptin/kisspeptin receptor system in the ovary 74
11.35 PIK3CA KRAS HRAS
43
Integrated cancer pathway 74
11.34 TP53 PTEN BRCA1
44
Syndecan-2-mediated signaling events 61
11.28 NF1 MMP2 HRAS
45
Regulation of Ras family activation 61
Show member pathways
 11.25 NF1 KRAS HRAS
46
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 74
11.15 PTEN PIK3CA KRAS HRAS
47
Bladder cancer 74
10.96 TYMP TP53 MMP2 KRAS HRAS
48
Pathways affected in adenoid cystic carcinoma 74
10.89 TP53 PTEN PIK3CA HRAS BRCA1 ARID1A
49
TNF-alpha signaling pathway 74
Show member pathways
 10.78 KRAS HRAS
Sources

GO Terms for Serous Cystadenocarcinoma

About this section

Cellular components related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 8.92 BRCA2 BRCA1

Biological processes related to Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.21 WT1 TP53 PTEN NF1 MIR21 HRAS
2 heart development GO:0007507 10.15 MMP2 NF1 PTEN TP53 WT1
3 negative regulation of gene expression GO:0010629 10.14 TP53 PIK3CA MIR21 MIR199A1 HRAS
4 cell migration GO:0016477 10.12 PTEN PIK3CA NF1 MMP2 MMP14
5 phosphatidylinositol 3-kinase signaling GO:0014065 10.07 PTEN PIK3CA NF1
6 cellular response to ionizing radiation GO:0071479 10.01 TP53 BRCA2 BRCA1
7 Ras protein signal transduction GO:0007265 10.01 TP53 NF1 KRAS HRAS
8 fibroblast proliferation GO:0048144 10 TP53 NF1 HRAS
9 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.98 NF1 MMP2 MIR21
10 neuron apoptotic process GO:0051402 9.92 HRAS KRAS NF1 TP53
11 cellular response to gonadotropin stimulus GO:0071371 9.91 WT1 PAX8
12 cellular response to gamma radiation GO:0071480 9.88 TP53 MIR21 HRAS
13 metanephric epithelium development GO:0072207 9.86 PAX8 WT1
14 metanephric S-shaped body morphogenesis GO:0072284 9.85 PAX8 WT1
15 cell population proliferation GO:0008283 9.83 TP53 PTEN NF1 KRAS BRCA2
16 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.76 PAX8 MIR21 MIR199A1
17 chordate embryonic development GO:0043009 9.74 BRCA2 BRCA1
18 regulation of long-term neuronal synaptic plasticity GO:0048169 9.73 NF1 KRAS HRAS
19 forebrain astrocyte development GO:0021897 9.67 NF1 KRAS
20 glial cell proliferation GO:0014009 9.55 TP53 NF1 KRAS
21 regulation of synaptic transmission, GABAergic GO:0032228 9.43 PTEN NF1 KRAS
22 angiogenesis GO:0001525 9.4 TYMP PTEN PIK3CA NF1 MMP2 MMP14
Sources

Sources for Serous Cystadenocarcinoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....